

AF IFW 1646/18


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 27, 2007

Signature:

(Sharon M. Sintien)

Docket No.: 01017/40451B
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Sharon M. Sintien et al.

Application No.: 08/444,790

Filed: May 19, 1995

For: HUMAN TNF RECEPTOR

Confirmation No.: 5612

Art Unit: 1646

Examiner: Z. Howard

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Documents C178-C184 are copies of papers relating to an opposition proceeding against European Patent No. 0939121 and copies of these documents are submitted herewith. The opposed European patent is a divisional application of European Patent No. 4175631 (European Application No. 90116707.2), which is a priority document for the above-identified patent application. The oral hearing for this opposition was held October 27, 2006. The outcome of this hearing, which is not yet published and may be appealed, is that all claims are maintained in their allowed form except claim 11.

Documents C24, C103, C162, and C176 are repeated in the attached Form PTO-1449. The original listing of these references omitted some bibliographical information

03/06/2007 AWONDAF1 00000070 00444790

01 FC:1806

100.00 DP


regarding the document. Applicants believe that the citations are now complete. Copies of these documents have been submitted with previous Information Disclosure Statements.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

This information disclosure statement is filed after the mailing of a first office action on the merits. Enclosed please find a check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 01017/40451B. A duplicate copy of this paper is enclosed.


Dated: February 27, 2007

Respectfully submitted,

By 
Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant



Form PTO-1449 (Modified)	Atty. Docket No. 01017/40451B	Serial No. 08/444,790
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Manfred Brockhaus et al.	
	Filing Date May 19, 1995	Art Unit 1646

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No

OTHER DOCUMENTS

	C24	Heller et al., Abstract at the 2 nd International Conference on Tumor Necrosis Factor and Related Cytokines, Napa Valley, California, January 15-20, 1989.
	C103	Loetscher et al., Two Distinct Human TNF Receptors: Purification, Molecular Cloning and Expression, 3 rd International Conference on Tumor Necrosis Factor and Related Cytokines, Makuhari, Chiba, Japan, November 21-25, 1990.
	C162	Inflammation & Infection: Rheumatoid Arthritis, Drug & Market Development, 67-70 (March, 2003).
	C176	Barone et al., Arthritis Rheum., 42(9)Suppl, September 1999, Abstract 116.
	C178	IPS Notice of Opposition to EP 0 939 121 and Statement in Support of the Opposition against EP 0939121
	C179	Patentee's Response to Notice of Opposition Request for Oral Hearing, dated August 3, 2004 (with translation)
	C180	Answer of the Opponent on the Admissibility of the Oppositions, dated November 3, 2004
	C181	Response to Patentee's Written Submission, dated July 22, 2005
	C182	Opponent's Observations Under R 71a EPC, dated September 22, 2006
	C183	AHP Comments on Oral Hearing and Preliminary Opinion, dated September 22, 2006

EXAMINER:	DATE CONSIDERED:
-----------	------------------



Form PTO-1449 (Modified)

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No.

01017/40451B

Serial No.

08/444,790

Applicant(s)

Manfred Brockhaus et al.

Filing Date

May 19, 1995

Art Unit

1646

C184

AHP Response to Opponent's Observations, dated October 6, 2006

EXAMINER:

DATE CONSIDERED: